New malaria vaccine vivaxin enters first human tests
NCT ID NCT07172724
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This early-stage trial is testing a new vaccine called Vivaxin, designed to protect against malaria caused by the Plasmodium vivax parasite. Researchers will give the vaccine to 48 healthy adults who have never had malaria, to check if it is safe and whether it triggers an immune response. The study is not yet recruiting and will compare the vaccine against a placebo.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Vivaxin vaccine (a lyophilized antigen mixed with an adjuvant called CTVad)
What this could lead to
If successful, this could lead to a vaccine that prevents malaria caused by Plasmodium vivax, a major cause of illness worldwide.
What could go wrong
This is a very early Phase 1 trial with only 48 people, so it is primarily checking safety and immune response, not whether the vaccine actually prevents malaria. Many vaccines fail at this stage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALARIA VIVAX are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Centro de Pesquisas Clínicas (CPC) do Hospital das Clínicas (HC) da UFMG/ Filial Ebserh
Belo Horizonte, Minas Gerais, 30130-100, Brazil
Contact Phone: •••-•••-•••• Email: •••••@•••••